Buchs, Switzerland

Irene Vaulont

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Philera New Zealand Limited, Gruenenthal Gmbh, Protemix Corporation Limited. Active years: 2009-2023.

USPTO Granted Patents = 7 

% Patents Active = 42.9

 

 

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2009-2023

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Irene Vaulont: Innovator in Triethylenetetramine Synthesis

Introduction

Irene Vaulont is a notable inventor based in Buchs, Switzerland. She has made significant contributions to the field of chemistry, particularly in the synthesis of triethylenetetramines. With a total of 7 patents to her name, her work has advanced the understanding and application of these compounds.

Latest Patents

Irene's latest patents focus on the synthesis of triethylenetetramines. These include methods and intermediates for synthesizing triethylenetetramine and its salts, as well as novel triethylenetetramine salts and their crystal structures. Additionally, her patents cover triethylenetetramine salts of high purity, showcasing her innovative approach to chemical synthesis.

Career Highlights

Throughout her career, Irene has worked with various companies, including Philera New Zealand Limited and Protemix Corporation Limited. Her experience in these organizations has allowed her to collaborate on groundbreaking projects and further her research in the field.

Collaborations

Irene has collaborated with notable coworkers such as Marco Jonas and Antonio Soi. Their combined expertise has contributed to the success of her innovative projects.

Conclusion

Irene Vaulont's contributions to the synthesis of triethylenetetramines highlight her role as a leading inventor in her field. Her patents and collaborations reflect her commitment to advancing chemical research and innovation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…